我国进展期胃癌围手术期行预防性腹腔热灌注化疗的研究进展

胃癌是我国最常见的恶性肿瘤之一, 术后5年生存率仅为10%~49%, 术后腹膜复发是影响其生存率的主要原因。腹腔热灌注化疗经过20多年的研究和发展, 已得到了充分的认识和较好的临床应用效果。预防性应用腹腔热灌注化疗有助于减少术后复发率, 提高胃癌的5年生存率, 改善生存质量, 提升胃癌的总体疗效。本文对近年来我国对进展期胃癌AGC行预防性腹腔热灌注化疗(hyperthermic intraperitonral chemotherapy, HIPEC)的临床开展情况作一综述。 

Progress in Preventive Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer in China

Gastric adenocarcinoma is one of the most common malignant tumors and is ranked third in cancer death toll following lung cancer and liver cancer in China. At least two thirds of the new cases with gastric cancer every year are at the advanced stage (AGC, advanced gastric cancer), and the postoperative 5-year survival rate is only 10% to 49%. The peritoneal relapse in the abdominal cavity is the major cause of unfavorable survival rate in these patients, even after radical operation. Over the past 20 years, hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved considerable success in treating gastric carcinoma with peritoneal carcinomatosis. Preventive application of HIPEC for gastric cancer can decrease the peritoneal recurrence, increase the current 5-year survival length, and improve the patients' quality of life. This review summarized the current status of preventive HIPEC for the treatment of locally advanced gastric cancer in China.